Safety |
Potential of spontaneous transformation and transfer of animal pathogens [9–11] is limited by avoiding in vitro culture. |
Potential carry-over of undesirable phenotypic characteristics in case of FH [57,58]. |
Purity |
Cells are not subject to in vitro aging associated with culture expansion [8,59], therefore no or minimal loss of native phenotypic [21,60] and functional characteristics. |
Currently-achieved purity levels are unlikely to be sufficient for allogeneic use. |
Cost |
Reduced cost due to lower regulatory burden [12] and reduced use of GMP-grade culture facilities and reagents. |
Total cost is dependent on the application and the numbers of MSCs required; these may be limited by the source material. |
Time |
Cells are ready for use within hours and do not require a lengthy expansion period. |
For autologous use extraction/enrichment procedure must fit with intraoperative time frame. |